FDA Delays Decision On AstraZeneca PLC’s Motavizumab To August 27th

June 25, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

LONDON, June 25 (Reuters) - U.S. regulators have deferred a decision on AstraZeneca's (AZN.L) experimental infant lung drug motavizumab for two months, after outside advisers recommended against its approval in a panel review on June 2.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory

AstraZeneca Pharmaceuticals LP Food and Drug Administration (FDA)